Marketing That Survives Review: How MedTech Startups Build Awareness Before Clearance

Marketing That Survives Review: How MedTech Startups Build Awareness Before Clearance

MedTech founders and CEOs can build awareness before clearance. A shared claims library and one weekly review window keep you visible without risking a claim.

Category

Marketing

Marketing

Publish Date

Author

Steph Pliha

Steph Pliha

Before clearance, a library of approved messages and one weekly review window can keep your company visible without sending every post back for another round.

Your regulatory lead just sent back the third LinkedIn draft this month. Every note on it was fair. One sentence sounded like a performance claim, another hinted at availability, and a third used a word that's on the team's avoid list. Meanwhile, the hospital buyer you met on Tuesday searched your company that evening and found a quiet website and a company page that hasn't posted in weeks.

Nobody in that story did anything wrong. Regulatory protected the company, and marketing tried to keep it visible. What's missing is a shared system that lets both of them do their jobs at the same time.

We hear some version of this from MedTech founders and CEOs who are six to eighteen months from clearance. In two client conversations this month alone, teams waiting on an FDA decision asked us how to build awareness when they can't talk about what the product does. Across our client work this fall, claims and approval cycles slowing promotion has been one of the problems we hear about most.

Why the Quiet Months Cost More Than They Look

It's tempting to treat the months before clearance as a waiting room. The plan is to go quiet, finish the submission, and launch loudly once the letter arrives.

The trouble is that buyers keep researching while you wait. Gartner surveyed 750 B2B buyers involved in complex purchases and found they spend only about 17% of their buying time meeting with potential suppliers. When they're comparing several suppliers, any one sales rep may get only 5% or 6% of that time. The rest goes to independent research and conversations inside the buying group. (Gartner)

In MedTech, that buying group includes clinicians, value analysis, supply chain, and finance, along with the investors and partners watching you from the side. If all they find before clearance is silence, you'll launch to a market that's meeting you for the first time.

What You Can Talk About Before Clearance

The rules depend on your pathway, and your regulatory lead decides how they apply to your device. Two of them are worth knowing as you plan.

FDA's long-standing compliance policy on premarket notification says a company may advertise or display a device while its 510(k) is pending, but it can't take orders, or be prepared to take orders, unless they're limited to research or investigational use. (FDA CPG Sec. 300.600) Investigational devices are held to a stricter line. Under 21 CFR 812.7, a sponsor can't promote or test market an investigational device, or represent it as safe or effective for the purpose it's being studied for. (eCFR)

Within those limits, most pre-clearance companies have more to say than they're using.

  • The clinical problem. Describe how it shows up today, who it affects, and what care teams do to work around it. Back every evidence statement with published literature.

  • The people. Introduce the founders, engineers, and clinical advisors behind the work, with their permission, and explain why they took it on.

  • The process. Share the milestones you've already announced publicly, what you're learning along the way, and what the path to market looks like. Keep to questions and progress rather than conclusions about performance.

  • Your point of view. Talk about where care is heading and what has to change for patients and clinicians. Your judgment about the market belongs to you, and it doesn't depend on a clearance letter.

What stays out is just as clear: anything about performance, safety, or effectiveness, comparisons with other devices, and language that suggests the product is available to buy.

Build a Claims Library Your Whole Team Can Use

In our experience, a lot of review time goes to rewriting the same ideas in slightly different words, then reviewing each version from scratch. A claims library ends that loop.

A claims library is one shared document that holds every statement your company makes about the problem, the product, and the evidence. Each entry carries its approved wording, its source, where it can be used, and who owns it. We'd organize it into three sections.

  • Say now. Approved statements about the problem, the team, the mission, and the process, each with a citation where one is needed. This is what fills your calendar before clearance.

  • Hold until clearance. Draft language that follows your submitted indication. It stays locked until FDA's decision, then gets updated to mirror the cleared wording exactly, because that's the wording your post-clearance copy has to follow.

  • Don't say. The words and phrases your team has agreed to avoid, with a short note on why. Writing them down heads off a lot of back-and-forth.

The real value shows up when everyone pulls from the same place. The founder's LinkedIn post, the sales deck, the conference booth, the website, and the agency's drafts all start from approved language, so they tell the same story. If your team uses AI to help with first drafts, the library gives it approved wording to work from, and a person still checks every line before it goes out.

Give Review a Rhythm

The second half of the system is time. Put one review window on the calendar each week, at the same time, with the same people, and route every piece of content through it.

Batching changes the experience for everyone. Anything built from library wording moves quickly, because it was approved once already. Only new statements need a full review, and once they're approved, they go into the library. The library gets a little bigger every week, so review gets a little lighter.

Your team also stops guessing when something will come back. Posts can be planned a few weeks ahead, the founder knows exactly when their input is needed, and regulatory sees content in one predictable block instead of a steady stream of urgent requests.

A Simple Place to Start This Week

  1. Gather the last ten pieces of content regulatory has approved and copy the approved sentences into one shared document. That's the first version of your library.

  2. Write five statements about the clinical problem, each with a published source, and get them approved once.

  3. Ask your regulatory lead for the words they flag most often, and start the "Don't say" list.

  4. Book a recurring weekly review window and send everything through it.

  5. Plan next month's posts from the "Say now" section first.

If you finish those five steps, you'll have enough approved material for weeks of posts, and every one of them will survive review.

Be Known Before the Letter Arrives

Clearance is a milestone the market should already understand when it happens. In our experience, the companies that launch well are usually the ones buyers, clinicians, and investors have watched explain the problem for months.

So picture that buyer from Tuesday searching your name again next quarter. With a library and a weekly rhythm, they'll find a company that clearly understands the problem and the people living with it, and they'll know who to call when the news lands.

This is work we do with MedTech founders and CEOs before and after clearance. Our founder, Steph Pliha, has 25 years in MedTech, including bringing robotic surgery to market. If you'd like a second set of eyes on what your team can say today, get in touch with Tribe

Read more

Join the Tribe List

Join the Tribe List

Join our newsletter for tips, updates, and project highlights—only the good stuff.
Join our newsletter for tips, updates, and project highlights—only the good stuff.